CR8827A - Compuesto heterociclico fusionado - Google Patents

Compuesto heterociclico fusionado

Info

Publication number
CR8827A
CR8827A CR8827A CR8827A CR8827A CR 8827 A CR8827 A CR 8827A CR 8827 A CR8827 A CR 8827A CR 8827 A CR8827 A CR 8827A CR 8827 A CR8827 A CR 8827A
Authority
CR
Costa Rica
Prior art keywords
heterociclic
compound
fused
formula
relates
Prior art date
Application number
CR8827A
Other languages
English (en)
Inventor
Ishikawa Tomoyasu
Taniguchi Takahiko
Banno Hiroshi
Seto Masaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR8827A publication Critical patent/CR8827A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a un compuesto representado pir la formula (I)
CR8827A 2004-06-02 2006-12-22 Compuesto heterociclico fusionado CR8827A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004165050 2004-06-02
JP2005058231 2005-03-02

Publications (1)

Publication Number Publication Date
CR8827A true CR8827A (es) 2007-04-20

Family

ID=35462874

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8827A CR8827A (es) 2004-06-02 2006-12-22 Compuesto heterociclico fusionado

Country Status (18)

Country Link
US (4) US7507740B2 (es)
EP (1) EP1752457B1 (es)
JP (2) JP4134227B2 (es)
KR (1) KR101194622B1 (es)
AU (1) AU2005250285B2 (es)
BR (1) BRPI0511768A (es)
CA (1) CA2569016C (es)
CR (1) CR8827A (es)
GE (1) GEP20105024B (es)
IL (1) IL179414A (es)
MA (1) MA28973B1 (es)
ME (1) MEP8409A (es)
MX (1) MXPA06013996A (es)
NO (1) NO20066015L (es)
NZ (1) NZ551938A (es)
RU (1) RU2389731C2 (es)
TW (1) TWI392679B (es)
WO (1) WO2005118588A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
AU2006272876A1 (en) * 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
US20080161320A1 (en) * 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
US20100008912A1 (en) * 2006-10-06 2010-01-14 Takeda Pharmaceutical Company Limited Combination drug
CN101611041A (zh) 2006-12-12 2009-12-23 武田药品工业株式会社 稠合杂环化合物
US7825127B2 (en) * 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
AU2008236670B2 (en) * 2007-04-05 2011-12-01 Amgen Inc. Aurora kinase modulators and method of use
JP5603770B2 (ja) 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
AU2008264469A1 (en) * 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
TW200942544A (en) * 2008-03-03 2009-10-16 Takeda Pharmaceutical Combination drug
UY31704A (es) * 2008-03-12 2009-11-10 Takeda Pharmaceutical Compuesto heterociclico fusionado
JP2011515401A (ja) * 2008-03-20 2011-05-19 アムジエン・インコーポレーテツド オーロラキナーゼモジュレーターおよび使用方法
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
WO2010036910A1 (en) * 2008-09-26 2010-04-01 Yoshikazu Ohta Heart protection by administering an amp-activated protein kinase activator
WO2010036917A1 (en) * 2008-09-26 2010-04-01 Takeda Pharmaceutical Company Limited Prevention and treatment of cancer with ras gene mutation
AR073679A1 (es) * 2008-09-26 2010-11-24 Takeda Pharmaceutical Prevencion y tratamiento de cancer con la no expresion de lkb1 supresion o mutacion, composicion farmaceutica. usos
JP2012512834A (ja) 2008-12-19 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症、喘息及びｃｏｐｄの処置のためのｃｃｒ２受容体アンタゴニストとしての環状ピリミジン−４−カルボキサミド
RS53012B (en) 2009-01-30 2014-04-30 Takeda Pharmaceutical Company Limited CONDENSED RING UNIT AND ITS USE
EP2471793B1 (en) * 2009-08-26 2016-10-05 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011040212A1 (en) 2009-10-01 2011-04-07 Takeda Pharmaceutical Company Limited Therapeutic agent for brain tumor
CN102933579B (zh) 2009-12-17 2015-07-15 贝林格尔.英格海姆国际有限公司 新的ccr2受体拮抗剂及其用途
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
JP5636094B2 (ja) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
WO2011151251A1 (en) 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
CA2760174A1 (en) * 2011-12-01 2013-06-01 Pharmascience Inc. Protein kinase inhibitors and uses thereof
TWI606049B (zh) * 2011-04-21 2017-11-21 原真股份有限公司 新穎激酶抑制劑
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
AU2014296261B2 (en) * 2013-07-31 2018-11-15 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof
US10040780B2 (en) * 2014-03-03 2018-08-07 The Regents Of The University Of California Mcl-1 antagonists
AU2015249496A1 (en) 2014-04-25 2016-09-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
CU24401B1 (es) 2014-05-01 2019-05-03 Novartis Ag Compuestos derivados de metoxibencil-pirrolopirimidin-amina como agonistas del receptor tipo toll 7 (tlr7)
ES2908150T3 (es) 2014-05-01 2022-04-27 Novartis Ag Compuestos y composiciones como agonistas del receptor de tipo Toll 7
ES2811098T3 (es) 2015-07-02 2021-03-10 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidin-1-il)(5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2hpirano-2-il) metilamino)pirimidin-4il) metanona
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3591845B1 (en) * 2018-07-05 2023-08-09 Universite De Bretagne Sud Sorting device and method for elementary check node processing for message-passing decoding of non-binary codes
WO2020118183A1 (en) * 2018-12-06 2020-06-11 Kapoor Tarun M 2,4-diaminopyrimidine bicycles for treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS554116B2 (es) * 1971-08-20 1980-01-29
CN1041631C (zh) * 1993-06-21 1999-01-13 默里尔药物公司 用作炎症前细胞因子选择性抑制剂的新的碳环核苷药物
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ES2203642T3 (es) * 1995-06-07 2004-04-16 Pfizer Inc. Derivados de pirimidina heterociclicos con anillos condensados.
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
DK0836605T3 (da) * 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EP0892789B2 (en) * 1996-04-12 2009-11-18 Warner-Lambert Company LLC Irreversible inhibitors of tyrosine kinases
CN1230185A (zh) 1996-07-13 1999-09-29 葛兰素集团有限公司 双环芳杂环化合物用作蛋白质酪氨酸激酶的抑制剂
CA2262421C (en) * 1996-08-23 2007-10-02 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
JPH10130258A (ja) 1996-10-10 1998-05-19 Eli Lilly & Co ベンゾ［ｂ］チオフェン化合物、中間体、製剤、および方法
EP0946554A1 (en) 1996-11-27 1999-10-06 Pfizer Inc. Fused bicyclic pyrimidine derivatives
TR200000333T2 (tr) 1997-08-05 2000-05-22 Pfizer Products Inc. Y alıcı antagonistleri olarak 4-aminopirol (3,2-d) pirimidinler.
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO2000005234A1 (fr) * 1998-07-22 2000-02-03 Suntory Limited INHIBITEURS DE NF-λB CONTENANT DES DERIVES D'INDANE EN TANT QU'INGREDIENT ACTIF
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
WO2001018170A2 (en) * 1999-08-26 2001-03-15 Plant Research International B.V. Conditional inhibition of vegetative propagation
RU2003134646A (ru) 2001-04-30 2005-04-20 Глэксо Груп Лимитед (GB) Конденсированные пиримидины в качестве антагонистов кортикотропинвысокобождающего фактора (crf)
ES2301633T3 (es) 2001-04-30 2008-07-01 Glaxo Group Limited Pirimidinas condensadas como antagonistas del factor de liberacion de corticotropina (crf).
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
JP2003183283A (ja) * 2001-12-18 2003-07-03 Takeda Chem Ind Ltd 縮合インドール化合物、その製造法および用途
EP1348707B1 (en) 2002-03-28 2010-08-25 Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
CA2527017A1 (en) 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
JP2006020985A (ja) 2004-07-05 2006-01-26 Kiyoshi Owada 微小孔を用いた入浴剤用炭酸ガス拡散装置
RU2007107167A (ru) * 2004-07-30 2008-09-10 Метилджин, Инк. (Ca) Ингибиторы передачи сигнала рецептора vegf и рецептора hgf
KR101078968B1 (ko) * 2005-05-20 2011-11-01 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제
TW200730527A (en) 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
US20100008912A1 (en) 2006-10-06 2010-01-14 Takeda Pharmaceutical Company Limited Combination drug
AU2008264469A1 (en) * 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
UY31704A (es) 2008-03-12 2009-11-10 Takeda Pharmaceutical Compuesto heterociclico fusionado

Also Published As

Publication number Publication date
EP1752457A4 (en) 2010-05-26
NZ551938A (en) 2010-07-30
AU2005250285B2 (en) 2011-08-18
AU2005250285A1 (en) 2005-12-15
US20090029973A1 (en) 2009-01-29
KR20070026695A (ko) 2007-03-08
JPWO2005118588A1 (ja) 2008-04-03
TW200611907A (en) 2006-04-16
EP1752457B1 (en) 2014-03-19
GEP20105024B (en) 2010-06-25
CA2569016C (en) 2012-11-27
BRPI0511768A (pt) 2008-01-08
MXPA06013996A (es) 2007-02-08
US20090018335A1 (en) 2009-01-15
WO2005118588A1 (ja) 2005-12-15
MA28973B1 (fr) 2007-11-01
RU2389731C2 (ru) 2010-05-20
IL179414A (en) 2013-11-28
MEP8409A (en) 2011-12-20
EP1752457A1 (en) 2007-02-14
US8178543B2 (en) 2012-05-15
JP4937172B2 (ja) 2012-05-23
IL179414A0 (en) 2007-05-15
JP2008247907A (ja) 2008-10-16
KR101194622B1 (ko) 2012-10-29
CA2569016A1 (en) 2005-12-15
US7507740B2 (en) 2009-03-24
US20070244132A1 (en) 2007-10-18
NO20066015L (no) 2007-02-13
JP4134227B2 (ja) 2008-08-20
RU2006147267A (ru) 2008-07-20
US20090203717A1 (en) 2009-08-13
TWI392679B (zh) 2013-04-11

Similar Documents

Publication Publication Date Title
CR8827A (es) Compuesto heterociclico fusionado
CY1112705T1 (el) Συντηγμενες κυκλικες ενωσεις
CR9369A (es) Compuestos de peridil acido acetico
CY1111671T1 (el) Ετεροκυκλικη ενωση
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CY1112767T1 (el) Κυκλικο παραγωγο κινναμιδιου
PA8649401A1 (es) Analogos de anilino-pirimidina
HRP20120323T1 (en) Diarylhydantoin compounds
UY28290A1 (es) Compuestos farmacéuticos novedosos
RS53003B (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
CY1113029T1 (el) Παραγωγα αζαδικυκλο [3.1.0] εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
CR8475A (es) Fenilalanina-amidas sustituidas por benzoilo
TW200730490A (en) Photoactive compounds
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
CR11454A (es) Derivados de isoxazolo-piridina
UY28625A1 (es) Nuevos compuestos farmacéuticos
CR9947A (es) Compuestos de pirimidinil benzotiofeno
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
RS52255B (en) NALMEFEN HYDROCHLORIDE DIHYDRATE
TW200613256A (en) Photoactive compounds
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
CY1111978T1 (el) Συζυγη μακρολιδων με αντιφλεγμονωδη δραση
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины